RT Journal Article
SR Electronic
T1 Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.02.01.929976
DO 10.1101/2020.02.01.929976
A1 Changhai Lei
A1 Wenyan Fu
A1 Kewen Qian
A1 Tian Li
A1 Sheng Zhang
A1 Min Ding
A1 Shi Hu
YR 2020
UL http://biorxiv.org/content/early/2020/02/02/2020.02.01.929976.abstract
AB A novel coronavirus, designated as 2019-nCoV, emerged in Wuhan, China, at the end of 2019. As of Feb 1, 2020, at least 11,844 cases had been diagnosed in China, however, there is no specific antiviral treatment or vaccine currently. Very recently report have suggest that novel CoV uses the same cell entry receptor, ACE2, as SARS-CoV. In this report, we generated a new recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronavirus and could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.